Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs . Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults .
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
• Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients.
• Treatment of symptomatic gastroesophageal reflux disease (GERD) in
patients 1 year of age and older
• Treatment of erosive esophagitis (EE) due to acid-mediated GERD in
patients 1 month of age and older
• Maintenance of healing of EE due to acid-mediated GERD in patients 1
year of age and older
• Pathologic hypersecretory conditions in adults
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders
- Conditions
- Constipation-predominant Irritable Bowel SyndromeFunctional Dyspepsia
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT05134584
- Locations
- 🇨🇳
RenJiH, Shanghai, Shanghai, China
Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05134350
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
- Conditions
- Healthy
- Interventions
- Drug: Aluminum/Magnesium Hydroxide/Simethicone
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT05109390
- Locations
- 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States
A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT05067439
- Locations
- 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
- Conditions
- Advanced Solid Tumours
- Interventions
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5
- Registration Number
- NCT04959266
- Locations
- 🇪🇸
Research Site, Malaga, Spain
High Dose Omeprazole in Patients With Pancreatic Cancer
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 60
- Registration Number
- NCT04930991
- Locations
- 🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 72
- Registration Number
- NCT04914936
Vonoprazan in Helicobacter Pylori Treatment an RCT
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Dow University of Health Sciences
- Target Recruit Count
- 179
- Registration Number
- NCT04901663
- Locations
- 🇵🇰
Dr Ruth KM Pfau Civil Hospital Karachi, Karachi, Sindh, Pakistan
A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 36
- Registration Number
- NCT04876807
- Locations
- 🇺🇸
Laura Sterling, MD, MPH, Lincoln, Nebraska, United States
A Study of LY3484356 in Healthy Female Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 82
- Registration Number
- NCT04840888
- Locations
- 🇺🇸
LabCorp CRU, Inc., Daytona Beach, Florida, United States
🇺🇸Covance Dallas, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.